Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19281795rdf:typepubmed:Citationlld:pubmed
pubmed-article:19281795lifeskim:mentionsumls-concept:C1334291lld:lifeskim
pubmed-article:19281795lifeskim:mentionsumls-concept:C0206131lld:lifeskim
pubmed-article:19281795lifeskim:mentionsumls-concept:C1456820lld:lifeskim
pubmed-article:19281795lifeskim:mentionsumls-concept:C1555029lld:lifeskim
pubmed-article:19281795lifeskim:mentionsumls-concept:C1999216lld:lifeskim
pubmed-article:19281795lifeskim:mentionsumls-concept:C0381241lld:lifeskim
pubmed-article:19281795lifeskim:mentionsumls-concept:C0301625lld:lifeskim
pubmed-article:19281795pubmed:issue2lld:pubmed
pubmed-article:19281795pubmed:dateCreated2009-4-6lld:pubmed
pubmed-article:19281795pubmed:abstractTextLipin-1 is a multifunctional metabolic regulator, involving in triacylglycerol and bioactive glycerolipids synthesis as an enzyme, transcriptional regulation as a coactivator, and adipogenesis. In obesity, adipose lipin-1 expression is decreased. Although lipin-1 is implicated in the pathogenesis of obesity, the mechanism is still not clear. Since TNF-alpha is deeply involved in the pathogenesis of obesity, insulin resistance, and diabetes, here we investigated the role of TNF-alpha on lipin-1 expression in adipocytes. Quantitative PCR studies showed that TNF-alpha suppressed both lipin-1A and -1B isoform expression in time- and dose-dependent manners in mature 3T3-L1 adpocytes. A Jak2 inhibitor, AG490, reversed the suppressive effect of TNF-alpha on both lipin-1A and -1B. In contrast, NF-kappaB, MAPKs, ceramide, and beta-catenin pathway tested were not involved in the mechanism. These results suggest that TNF-alpha could be involved in obesity-induced lipin-1 suppression in adipocytes and Jak2 may play an important role in the mechanism.lld:pubmed
pubmed-article:19281795pubmed:languageenglld:pubmed
pubmed-article:19281795pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19281795pubmed:citationSubsetIMlld:pubmed
pubmed-article:19281795pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19281795pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19281795pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19281795pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19281795pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19281795pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19281795pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19281795pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19281795pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19281795pubmed:statusMEDLINElld:pubmed
pubmed-article:19281795pubmed:monthMaylld:pubmed
pubmed-article:19281795pubmed:issn1090-2104lld:pubmed
pubmed-article:19281795pubmed:authorpubmed-author:KohgoYutakaYlld:pubmed
pubmed-article:19281795pubmed:authorpubmed-author:TannoSatoshiSlld:pubmed
pubmed-article:19281795pubmed:authorpubmed-author:TakahashiNobu...lld:pubmed
pubmed-article:19281795pubmed:authorpubmed-author:OkumuraToshik...lld:pubmed
pubmed-article:19281795pubmed:authorpubmed-author:MotomuraWatar...lld:pubmed
pubmed-article:19281795pubmed:authorpubmed-author:TsuchiyaYoshi...lld:pubmed
pubmed-article:19281795pubmed:authorpubmed-author:TannoSachieSlld:pubmed
pubmed-article:19281795pubmed:authorpubmed-author:TakakusakiKao...lld:pubmed
pubmed-article:19281795pubmed:authorpubmed-author:OhhiraMasumiMlld:pubmed
pubmed-article:19281795pubmed:authorpubmed-author:YoshizakiTaka...lld:pubmed
pubmed-article:19281795pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19281795pubmed:day1lld:pubmed
pubmed-article:19281795pubmed:volume382lld:pubmed
pubmed-article:19281795pubmed:ownerNLMlld:pubmed
pubmed-article:19281795pubmed:authorsCompleteYlld:pubmed
pubmed-article:19281795pubmed:pagination348-52lld:pubmed
pubmed-article:19281795pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:19281795pubmed:meshHeadingpubmed-meshheading:19281795...lld:pubmed
pubmed-article:19281795pubmed:meshHeadingpubmed-meshheading:19281795...lld:pubmed
pubmed-article:19281795pubmed:meshHeadingpubmed-meshheading:19281795...lld:pubmed
pubmed-article:19281795pubmed:meshHeadingpubmed-meshheading:19281795...lld:pubmed
pubmed-article:19281795pubmed:meshHeadingpubmed-meshheading:19281795...lld:pubmed
pubmed-article:19281795pubmed:meshHeadingpubmed-meshheading:19281795...lld:pubmed
pubmed-article:19281795pubmed:meshHeadingpubmed-meshheading:19281795...lld:pubmed
pubmed-article:19281795pubmed:meshHeadingpubmed-meshheading:19281795...lld:pubmed
pubmed-article:19281795pubmed:meshHeadingpubmed-meshheading:19281795...lld:pubmed
pubmed-article:19281795pubmed:meshHeadingpubmed-meshheading:19281795...lld:pubmed
pubmed-article:19281795pubmed:year2009lld:pubmed
pubmed-article:19281795pubmed:articleTitleA Jak2 inhibitor, AG490, reverses lipin-1 suppression by TNF-alpha in 3T3-L1 adipocytes.lld:pubmed
pubmed-article:19281795pubmed:affiliationDepartment of General Medicine, Asahikawa Medical College, Asahikawa, Hokkaido, Japan.lld:pubmed
pubmed-article:19281795pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19281795pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:14245entrezgene:pubmedpubmed-article:19281795lld:entrezgene
entrez-gene:16452entrezgene:pubmedpubmed-article:19281795lld:entrezgene
entrez-gene:21926entrezgene:pubmedpubmed-article:19281795lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19281795lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19281795lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19281795lld:entrezgene